A detailed history of Bank Of America Corp transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 199 shares of IKNA stock, worth $312. This represents 0.0% of its overall portfolio holdings.

Number of Shares
199
Previous 327 39.14%
Holding current value
$312
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.6 - $1.85 $204 - $236
-128 Reduced 39.14%
199 $0
Q2 2024

Aug 14, 2024

SELL
$1.24 - $1.82 $23,434 - $34,396
-18,899 Reduced 98.3%
327 $0
Q1 2024

May 15, 2024

SELL
$1.27 - $2.0 $39,060 - $61,512
-30,756 Reduced 61.53%
19,226 $27,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $4.4 $45,697 - $151,179
34,359 Added 219.93%
49,982 $98,000
Q2 2023

Aug 14, 2023

BUY
$3.5 - $7.31 $30,593 - $63,896
8,741 Added 127.01%
15,623 $102,000
Q1 2023

May 12, 2023

SELL
$2.62 - $4.97 $5,834 - $11,068
-2,227 Reduced 24.45%
6,882 $23,000
Q4 2022

Feb 10, 2023

BUY
$2.0 - $3.7 $16,984 - $31,420
8,492 Added 1376.34%
9,109 $24,000
Q3 2022

Nov 14, 2022

BUY
$3.46 - $6.0 $1,069 - $1,854
309 Added 100.32%
617 $2,000
Q2 2022

Aug 12, 2022

SELL
$3.23 - $7.4 $39,134 - $89,658
-12,116 Reduced 97.52%
308 $1,000
Q1 2022

May 16, 2022

SELL
$5.61 - $13.85 $68,542 - $169,219
-12,218 Reduced 49.58%
12,424 $75,000
Q4 2021

Feb 08, 2022

BUY
$10.52 - $16.96 $144,334 - $232,691
13,720 Added 125.62%
24,642 $309,000
Q3 2021

Nov 15, 2021

BUY
$9.82 - $15.23 $65,047 - $100,883
6,624 Added 154.12%
10,922 $138,000
Q2 2021

Sep 13, 2021

BUY
$13.27 - $26.0 $57,034 - $111,748
4,298 New
4,298 $60,000

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $56.9M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.